why is tirzepatide not fda approved Tirzepatide, the new medication for weight loss? FDA Says Shortage for GLP-1

Ambos medicamentos han demostrado eficacia en la reduccin de peso en ensayos clnicos, pero pueden variar en la magnitud y duracin de los resultados

Wegovy and Perimenopause: Weight Management During Menopausal Transition Wegovy and perimenopause represent an important intersection in women's health, as many women experience challenging weight gain during the menopausal transition

The FDA also approves 1.7 mg weekly as a maintenance dose for patients who cannot tolerate 2.4 mg

Tips for Long-Term Success Combine turmeric with balanced nutrition high in fiber and low in refined sugar

J., Syme, C

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema